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Abstract. The αβ T-cell co-receptor CD4 enhances immune responses more than one million-
fold in some assays, and yet the affinity of CD4 for its ligand, peptide-major histocompatibility 
class II (pMHC II) on antigen-presenting cells, is so weak that it was previously unquantifiable. 
Here, we report that a soluble form of CD4 failed to bind detectably to pMHC II in surface 
plasmon resonance-based assays, establishing a new upper limit for the solution affinity at 2.5 
mM. However, when presented multivalently on magnetic beads, soluble CD4 bound pMHC 
II-expressing B cells, confirming that it is active and allowing mapping of the native co-
receptor binding site on pMHC II. Whereas binding was undetectable in solution, the affinity 
of the CD4/pMHC II interaction could be measured in two dimensions (2D) using CD4- and 
adhesion molecule-functionalized, supported lipid bilayers, yielding a 2D dissociation 
constant, Kd, of ~5000 molecules/μm2. This value is 2-3 orders of magnitude higher than 
previously measured 2D Kd values for interacting leukocyte surface proteins. Calculations 
indicated, however, that CD4/pMHC II binding would increase rates of T-cell receptor (TCR) 
complex phosphorylation by three-fold via the recruitment of Lck, with only a small, 2-20% 
increase in the effective affinity of the TCR for pMHC II. The affinity of CD4/pMHC II 
therefore appears to be set at a value that increases T-cell sensitivity by enhancing 
phosphorylation, without compromising ligand discrimination. 
 
Significance statement 
The function of the T-cell co-receptor CD4 presents a long-standing puzzle. Although it is 
among the most potent modulators of immune responses, CD4 interacts with its binding 
partner, pMHC II, with previously unmeasurably-low affinity. Here, we set a new upper limit 
for the solution affinity of CD4 and pMHC II and show that the two-dimensional dissociation 
constant in supported lipid bilayers is as much as 2-3 orders of magnitude higher than that for 
other interacting leukocyte surface proteins. These findings extend the known physical limits 
of functional protein interactions at the cell surface and suggest new ways that T cells may 
utilize differential receptor affinities during antigen recognition and discrimination. 
 
 
Introduction 
αβ T cells comprise functionally distinct subsets depending on which transcription factors and 
which of two co-receptors, CD8 or CD4, they express. CD8+ T-cells respond to peptide 
agonists presented by major histocompatibility class I molecules (pMHC I) and are cytotoxic, 
whereas conventional CD4+ cells recognize peptide-MHC class II (pMHC II) and provide 
“help” defined by the cytokines they secrete (1). Cell adhesion assays explain this functionality 
insofar as CD8 and CD4 bind directly to pMHC I and pMHC II, respectively (2, 3). CD4 
comprises two pairs of V-set and C2-set immunoglobulin superfamily domains, with early 
mutational data showing that the “top” two domains bind pMHC II (4). Crystal structures of 
cross-species and affinity-matured CD4/pMHC II complexes suggest that CD4 binds a pocket 
formed by the α2 and β2 domains of pMHC II (5, 6). The role of co-receptors in heightening 
T-cell responses is well established. For example, whereas CD4+ T-cells can respond to single 
pMHC II complexes presented by antigen-presenting cells (APCs), 30 or more complexes are 
required if CD4 is blocked (7). 
 
How CD4 achieves these effects, however, is incompletely understood. Co-receptors are 
pivotal in recruiting the kinase Lck to T-cell receptor(TCR)/pMHC complexes (8, 9), but for 
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reasons that are unclear co-receptor/pMHC interactions are extraordinarily weak. 
Traditionally, weak protein interactions are characterized using surface plasmon resonance 
(SPR) measurements, where one protein is tethered to the sensor surface and over it the other 
is passed at various concentrations. The SPR-based affinity of CD8 for pMHC I is 50 to 200 μM 
(10). However, SPR has thus far failed to detect interactions between CD4 and pMHC II, 
setting a lower limit of the dissociation constant, Kd, at least two orders of magnitude higher 
than for typical interacting leukocyte-expressed proteins (5, 10, 11). 
 
Here, we use SPR assays to extend the upper limit of the CD4/pMHC II solution affinity. 
However, the interactions of proteins in solution may differ from those at contacts between two 
cells, or between a cell surface and model lipid bilayer (11–14). We therefore also analyzed the 
two-dimensional (2D) affinity of the CD4/pMHC II interaction for B-cells interacting with 
supported lipid bilayers (SLBs) containing fluorescently-labelled CD4 and the small T-cell 
adhesion protein CD2, used to create a physiological context for CD4/pMHC II binding. CD2 
is expressed by T cells and binds CD58 on B cells with much higher affinity than the 
CD4/pMHC II interaction (15, 16). Including CD2 ensured that CD4/pMHC II bonds had time 
to develop and reduced the risk of biasing the data toward cells with high avidity for CD4 (15).  
 
Other 2D Kd measurements have been made, but only for systems where the average Kd is 
significantly lower than that of CD4/pMHC II binding (12, 13, 16, 17). Here, we use the method 
of Zhu et al. (16) to measure the 2D Kd for the CD4/pMHC II interaction, which proves to the 
best of our knowledge to be the weakest such interaction ever studied. The surface density of 
CD4 bound to pMHC II on the B cell, B, is related to the surface density of free CD4 in the 
SLB beneath the cell, F, by the Zhu-Golan expression:  
 
  [1] 
 
where Nt and f are the number and mobile fraction of pMHC II molecules, respectively, Scell is 
the surface area of the cell and p is the ratio of the SLB/cell contact area to Scell. Measurements 
were also made for rat CD2 and CD48 for comparison and as a test of the CD4/pMHC II results. 
We finally consider why CD4/pMHC II binding is so weak and develop a mathematical model 
to investigate how it could affect the stability of TCR/pMHC II complexes and impact on rates 
of Lck recruitment and TCR phosphorylation. Our findings extend the known physical limits 
of functional protein interactions at the cell surface. 
 
 
Results 
Binding of soluble CD4 to pMHC II. We first tried to directly measure the binding affinity 
of CD4 for pMHC II molecules in SPR-based assays. For this, soluble biotinylatable human 
CD4 (sCD4) was expressed in mammalian cells ((18) see Materials and Methods). sCD4 bound 
stoichiometrically at distinct epitopes to two different mouse anti-human CD4 antibodies 
(ADP318 and RPA-T4; see Fig. S1A,B), and it also bound to HIV-1 gp120 (see Fig. S1C), 
indicating that it was homogeneous and correctly folded. sCD4 was injected at different 
concentrations at 37 °C over a sensor surface presenting immobilized HLA-
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DRB1*01:01/DRA*01 (DR1) pMHC II bound with influenza hemagglutinin (HA) peptide or 
HLA-A*24:02 (A24) pMHC I bound with a Dengue peptide (Den2) as a negative control (see 
Fig. 1A). The pMHC II proteins bound strongly to L243, a conformation-sensitive, pan anti-
human DR antibody (see Fig S2A), indicating that the pMHC II was functional. However, even 
at exceptionally high concentrations of sCD4 (up to 2.5 mM), no significant difference in 
response was detectable between the control and the pMHC II-containing flow cells (see Fig. 
1A). Injections at the highest concentration (2.5 mM) at 4 °C (to minimize dissociation) also 
gave no binding (see Fig. S2B). These measurements were repeated with two other pMHC II, 
i.e. HLA-DRB1*15:01/DRA*01 (DR2) bound with MBP peptide and HLA-
DRB1*04:01/DRA*01 (DR4) bound with EBV peptide, with the same outcome (see Fig. S3).  
 
To confirm that sCD4 could bind pMHC II we developed a multivalent binding assay. DR1, 
the beta chain of which was attached N-terminally to HA peptide and C-terminally to GFP (i.e. 
HA-DR1-GFP; see Fig. S4A), was expressed in HEK 293T cells. Biotinylated sCD4 
(sCD4biot) tetramerized with phycoerythrin-labelled streptavidin (SA) bound strongly to HEK 
293T cells expressing HIV-1 gp120-GFP, but not to cells expressing HA-DR1-GFP (see Fig. 
S4B). sCD4biot avidity was then increased by attaching it to SA-coated magnetic beads 
(~50,000 sCD4biot/bead) and used to “pull down” HA-DR1-GFP-expressing cells (Fig. 1B; 
example bead-bound cells are shown in Fig. 1C). Three- to four-fold more cells expressing 
HA-DR1-GFP could be recovered than cells expressing the DR1β chain or GFP-only (see Fig. 
1B), demonstrating binding of sCD4 to HA-DR1-GFP. However, this was only a quarter of the 
recoverable gp120-GFP-expressing cells (see Fig. 1B), emphasizing the very low affinity of 
CD4/pMHC II binding. The interaction was sensitive to mutations of residues clustered in the 
pocket between the α2 and β2 domains used by affinity-matured CD4 to bind DR1 and DR4 
(19), i.e. βI148, βL158, αT90 and αL92 (see Fig. 2, Fig. S4C and SI Text, Section 1). Mutations 
of residues analogous to those in pMHC I that bind CD8, i.e. βE137 and βV142, were disruptive 
as noted previously (20), due perhaps to indirect effects on the structure of the pocket. 
Mutations of αK126, αT129 and αT130 at a second site proposed to allow CD4/pMHC II 
complex oligomerization (21) were without effect, however, implying that CD4 does not bind 
this region. Overall these data are consistent with native CD4 binding pMHC II at the single 
site identified in structures of cross-species and affinity-matured CD4/pMHC II complexes, 
and with binding being undetectable in SPR experiments due to the very low solution affinity 
of this interaction.  
 
Binding of B cells to CD4 in lipid bilayers. SLBs containing different amounts of Alexa 
Fluor® 647-labelled, lipid-anchored CD4 (400 - 4000 molecules/µm2) were used to investigate 
CD4/pMHC II binding at the B-cell surface at room temperature (22 °C). Raji B-cells were 
added above the SLB and allowed to bind to the proteins in the SLB. To ensure firm contact, 
and to position the cell surface at physiologically-relevant distances (22), approximately 400 
molecules/µm2 of Alexa Fluor® 488-labelled, lipid-anchored CD2 was incorporated in the 
SLB. Video S1 shows B cells settling on an SLB containing 900 molecules/µm2 of CD4 and 
400 molecules/µm2 of CD2. 
 
Three types of SLB/B-cell contacts formed (see Fig. 3). Clear increases in CD2 fluorescence 
beneath the cells are observed in all three cases but, for case (i), the CD4 intensity decreases 
compared to outside the cell whereas in cases (ii) and (iii) it increases slightly (see also Fig. S5). 
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The distribution of cases is: (i) 22±15%, (ii) 52±12% and (iii) 26±11% (mean value ± one 
standard deviation from 12 experiments), where, from Fig. S5, case (i) is defined as cells to the 
left of the kink in the fitted curve, and case (ii) and (iii) as cells on the lower and upper half of 
the slope, respectively. In case (ii) it is also seen that under the cell, but outside the contact area 
given by the CD2 image (dotted contour in the bright-field image, Fig. 3), the intensity is 
significantly lower compared to outside the cell (see also SI Text, Section 2). The reason for 
this is that unbound CD4 is excluded from the cell-cell contact. Case (i) corresponds to an 
SLB/B-cell contact where no amount of CD4 binding is discernible. This behaviour is not 
limited to CD4 binding to B cells: CD4 depletion was observed in SLB contacts formed by 
pMHC II non-expressing Jurkat cells (see Fig. S6A), and rat CD2 added to the SLBs, which 
does not bind human B-cells, was depleted at B-cell contacts (see Fig. S6B). However, in these 
cases depletion only was observed, and not accumulation as observed for the SLB with CD4/B-
cell contacts (see case ii and iii in Fig. 3), indicating that CD4/pMHC II binding was being 
measured. Ligand depletion observed elsewhere has been attributed to steric crowding at the 
contact (17). This can significantly affect the analysis of binding affinity using Eq. 1 if not 
corrected for, especially when B/F < 1 (16, 17) (see SI Materials and Methods, Section 2 for 
details of how compensation was made). 
 
Zhu-Golan analysis of CD4/pMHC II binding. The amount of CD4 accumulation under 
different cells on a given SLB varied considerably (see Fig. S5), with the standard deviation of 
B/F for each experiment being ~70% of the mean. However, the mean value from different sets 
of experiments under similar conditions has a much smaller spread and is fairly reproducible 
(see Fig. 4). The variation therefore results from differences between the cells and their CD4 
avidity rather than measurement uncertainty. Plotting the mean value of B/F from each SLB 
resulted in the data shown in Fig. 4 for CD4/pMHC II binding and for rat CD2 (35 – 1600 
molecules/µm2) binding to rat CD48 (either wild-type (WT), or a weakly-binding mutant Q40R 
(23)). For the latter experiments CD48-transfected Jurkat T-cells were used and ~100 
molecules/µm2 of human CD58 was added to the SLBs to position the cells (see Figs. S6C,D).  
 
The experimental data were fitted to Eq. 1 with values of Nt and Scell determined as described 
in the Materials and Methods (see Table 1 for values), assuming a mobile fraction of f = 1. The 
only free parameter to fit is then Kd. This gave the following 2D Kd values: 4800 
molecules/µm2 for CD4/pMHC II (see also SI Text, Section 3), 38 molecules/µm2 for 
CD2/CD48 (WT) and 380 molecules/µm2 for CD2/CD48 (Q40R). To validate the analysis we 
also analysed the rat CD2/CD48 (WT) data using the standard Zhu-Golan method, where the 
slope of the data in Fig. 4 is used to determine Kd without knowing Nt, f and Scell (16). The 
observation that the two values were the same (38 molecules/µm2) indicated that our method 
of analysis was approximately valid, at least for the rat CD2/CD48 case. We did not use the 
Zhu-Golan analysis for all data sets because using the slope to determine the Kd value is less 
accurate for the weaker interactions since the slow change in B/F vs B×p is less than, or 
comparable to, the accuracy of the measurements for those cases. This is less of a problem 
when fixing Nt, f and Scell, which gives more accurate values for Kd assuming that the error in 
choosing Nt, f and Scell is not too large.  
 
The 2D Kd value for WT rat CD2/CD48 binding is similar in magnitude, but slightly smaller, 
than previous measurements (15). The 2D Kd value for the weak-binding Q40R mutant is ten-
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fold larger than that for the WT, similar to the ratio in the 3D Kd measurements (see Table 1). 
These interactions are weak compared to many other protein interactions between T-cells and 
APCs, as illustrated also by their relatively large 3D Kd values. However, the CD4/pMHC II 
2D Kd at 5000 molecules/µm2 is one to two orders of magnitude larger compared to these 
interactions, three orders of magnitude larger than that for human CD2/CD58 binding (17), and 
two to three orders of magnitude larger than that for TCR/pMHC interactions (13, 24). The 3D 
Kd values for the latter interactions is ~10 µM (10, 13, 24, 25), so it can be expected that the 
3D Kd for CD4/pMHC II binding should, similar to the 2D Kd, be two to three orders of 
magnitude larger than this value. This is in agreement with a lower limit of 2.5 mM for the 3D 
Kd of the CD4/pMHC II interaction measured here using SPR, although extrinsic factors such 
as the average distance between the two cell surfaces could in principle significantly affect 
binding in 2D vs 3D. Measurements of the CD4/pMHC II 2D Kd were also made at 37 °C. The 
B/F ratios from different SLBs were, within the accuracy of the experiments, similar to those 
at room temperature.  
 
A delimited area of the SLB/B-cell contact was bleached and recovery studied to investigate 
the dynamic behaviour of the CD4/pMHC II interaction (see Fig. S7). The fluorescence from 
free and bound CD4 almost completely recovered within 2 minutes indicating that the amount 
of trapped CD4 in the contact is small compared to the density of mobile molecules. From a fit 
of the recovery data (see Fig. S7B) an average diffusivity of D = 0.16±0.06 μm2/s (N = 4) was 
obtained for CD4 in the contact. This value is ten times smaller than that for free CD4 outside 
the contact (1.8±0.2 μm2/s; N = 4),most likely caused by a higher net drag of the protein in the 
contact, rather than specific CD4 binding events (see SI Text, Section 4 for details). 
 
Modelling of the effects of CD4 on TCR/pMHC II stability and phosphorylation rate. 
Different mathematical expressions were derived to investigate how the very weak CD4/pMHC 
II interaction affects T-cell sensitivity and the stability of ternary TCR/pMHC II complexes.  
 
(i) Effect of CD4 on Lck recruitment to non-phosphorylated TCRs. CD4-associated Lck (CD4-
Lck) can only phosphorylate the TCR complex when it is within a certain area, A, around the 
TCR/pMHC II. It can be assumed that Lck is within area A when CD4-Lck binds to pMHC II 
in a TCR/pMHC II pair, which means that bound CD4-Lck can phosphorylate the TCR/pMHC 
II complex an extra fraction Rt/Kc of the time (see SI Text, Section 5 for details), where Rt is 
the density of CD4-Lck and Kc is the 2D Kd of the CD4/pMHC II interaction. This results in 
the following formula for the overall rate of TCR phosphorylation by CD4-Lck, for which the 
second term is due to Lck recruitment: 
 
 ( )cLCK/TCRp,Lck/TCR-CD4p, 1 Kkk σ+=  [2] 
 
where kp, CD4-Lck/TCR and kp, Lck/TCR are the rates of TCR phosphorylation by CD4-Lck and Lck, 
respectively, and σ = 1/A is an effective local concentration corresponding to one molecule 
within area A. The actual size of A has not been experimentally determined, but is estimated to 
be of the order of 100 nm2, corresponding to σ = 10000 molecules/µm2 (8, 9, 26). This is also 
comparable to the area occupied by Lck in the CD4-Lck/TCR/pMHC II complex (19). With 
Kc = 5000 molecules/µm2, kp, CD4-Lck/TCR is a factor of three larger than kp, Lck/TCR.  
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(ii) Effect of CD4 on the stability and phosphorylation of ternary CD4-Lck/phosphorylated 
TCR/pMHC II complexes. Following TCR phosphorylation CD4-Lck can bind phosphorylated 
tyrosines in the TCR complex (27). To investigate how this can affect the recruitment of Lck 
and the stability of TCR/pMHC II in the ternary complex, we developed a mathematical model 
describing the equilibrium distribution of CD4-Lck, pMHC II and phosphorylated TCR (TCR-
P) in different binding states (see Fig. S8 and SI Text, Section 6). The number of TCR-P is 
assumed to be low early in T-cell responses, such that most CD4-Lck molecules are not bound 
to TCR-P. The increase in effective affinity of TCR for pMHC II, 1/Keff, in the presence of 
CD4 can, under these conditions, be shown to be (see SI Text, Section 6 for details): 
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where Kl and K are the 2D Kd values for binding of CD4-Lck to TCR-P and TCR-P to 
pMHC II, respectively. The parameter σ corresponds again to the local concentration of bound 
molecules in the complex (see also Eq. 2), which for simplicity was set to be equal for all three 
interactions. It has been assumed in Eq. 3 that both the concentration of pMHC II and Rt are 
significantly lower than Kc. The rightmost expression is approximately valid when Rt/Kl < 1. 
Inserting σ = 10000 molecules/µm2, Kc = 5000 molecules/µm2, and Rt/Kl = 0.01 to 0.1 (see SI 
Text, Section 6 for details on how Rt/Kl is estimated) into Eq. 3 gives an apparent affinity 
increase of 2% to 20%, respectively, when K << σ. CD4 will thus only modestly affect the 
stability of the TCR/pMHC II interaction under these conditions. 
 
Using the same assumptions and parameter values the increase in recruitment of CD4-Lck to 
TCR-P due to CD4/pMHC II binding can also be estimated. For Kl = 250 molecules/µm2 (28), 
the fraction of CD4-Lck-associated TCR-P/pMHC II increases by 2.6- and 3.0-fold for Rt/Kl 
= 0.1 and Rt/Kl = 0.01, respectively (see Eq. S18). The subsequent phosphorylation of the TCR 
complex, as well as phosphorylation of recruited ZAP70, will therefore also be increased by 
approximately 3-fold (see Eq. S17). It should finally be noted that, from Eq. S17 and Eq. 2 this 
phosphorylation rate (kp,CD4-Lck/TCR-P) is 30-40 times larger (depending on the value for Rt/Kl) 
than the initial rate of phosphorylation, i.e. of the unphosphorylated receptor (kp,CD4-Lck/TCR in 
Eq. 2).  
 
 
Discussion 
The binding of CD4 to pMHC II is remarkably weak compared to the interactions of other 
molecules expressed by T cells and APCs. Here, sCD4 monomers failed to bind pMHC II at 
concentrations as high as 2.5 mM. Since it is likely to be at least double the highest 
concentration tested, this sets a new lower limit for the solution Kd of 5 mM. To confirm that 
this measurement was reliable we established a binding assay wherein, in a highly multivalent 
form, sCD4 binding to cell-expressed pMHC II could be detected. Using this assay we 
confirmed that for native CD4 the binding site on pMHC II corresponds to that suggested by 
crystal structures of cross-species and affinity-matured CD4/pMHC II complexes (5, 6). It can 
therefore be assumed that native CD4 forms the same “v-shaped” complex that affinity-
matured CD4 forms with TCR/pMHC II, wherein contact with the TCR is seemingly precluded 
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(19). It thus seems very unlikely that the ternary CD4/pMHC II/TCR interaction is stabilised 
by direct interactions between the extracellular domains of CD4 and the TCR. 
 
To characterize binding in 2D approximating the conditions at T-cell/APC contacts, we studied 
the interactions of B cells with SLBs containing human CD4 and used CD2 to initially anchor 
and then position the cell on the SLB at a physiologically relevant distance. Zhu-Golan analysis 
gave a 2D Kd of ~5000 molecules/µm2 for the CD4/pMHC II interaction, the largest value ever 
reported for protein interactions at the cell surface. This value is two to three orders of 
magnitude larger than typical interactions between molecules expressed by T cells and APCs, 
but is still specific since CD4 in SLBs did not interact with cells lacking pMHC II. 
Photobleaching measurements showed that CD4/pMHC II binding is reversible, and that the 
mobility of CD4 in the contact is more than ten-fold lower compared to outside the contact. 
While the 2D off-rate (koff) for the CD4/pMHC II interaction could not be determined in the 
present experiments, it can be estimated to be of the order of 250 s-1 (see SI Text, Section 7 for 
details). With a 2D Kd value of 5000 molecules/µm2 this gives a 2D on-rate (kon) of 0.05 
µm2molecules-1s-1, which is comparable to that measured for protein-protein interactions of 
higher affinity between T cells and APCs (13, 29). However, the koff is orders of magnitude 
larger (12, 13, 29). 
 
The 2D Kd value obtained here corresponds to the equilibrium value when two cells, or lipid 
bilayers with proteins, are held with their surfaces positioned relative to each other at a distance 
similar to that in the synaptic contact between T cells and APCs. Other techniques involving, 
e.g. micropipettes to periodically bring cells containing the two proteins into contact (12, 30), 
have been used to study the binding kinetics of single bonds when the cells are not aligned. 
However, including stronger binding auxiliary molecules to align and position the contacting 
surface, such as rat CD2/CD48 in this work, would be problematic in pipette-based experiments 
since the binding kinetics of the auxiliary molecules would dominate the overall signal versus 
that for the specific CD4/pMHC II interaction. The 2D Kd value obtained for the CD4/pMHC 
II interaction could be different when T cells contact APCs rather than SLBs containing CD4 
and CD2. However, the observation that the CD4/pMHC II interaction is orders of magnitude 
weaker than typical T-cell/APC protein interactions is expected to hold. 
 
But what are the implications of the very large dissociation constant and how does CD4 so 
profoundly affect T-cell signalling? The important role of CD4 in vivo is believed to be the 
recruitment of Lck to the TCR (8, 9, 31). The recruited Lck would phosphorylate immune-
receptor-tyrosine-based-activation-motifs (ITAMs) constituting the initial step of T-cell 
activation (8, 9). In agreement with this, Xu and Littman found that T-cell responses were 
significantly reduced if CD4 could not bind pMHC II, and that this depended on CD4-Lck 
being able to bind phosphorylated tyrosines in the TCR (27). Hong et al. also recently showed 
that CD4 has a negligible effect on the affinity and lifetime of TCR/pMHC II complexes, 
indicating that the primary role of CD4 is not TCR/pMHC II stabilisation (30). To see whether 
our measured affinity of CD4 to pMHC II fits with these results we undertook numerical 
calculations to establish whether, in particular, (i) CD4 contributes to initial TCR 
phosphorylation (see Fig. 5A), and (ii) how the CD4/pMHC II interaction affects the effective 
affinity of the TCR for pMHC II and the recruitment of Lck to previously phosphorylated TCRs 
(see Fig. 5B). 
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The mathematical expressions showed that despite the very low affinity of CD4 for pMHC II 
it is sufficiently strong to increase the rate of phosphorylation of both unphosphorylated and 
previously phosphorylated TCRs up to 3-fold due to the recruitment of Lck. However, the 
effective affinity of the TCR for pMHC II only increased marginally (2-20%) under the same 
conditions, in agreement with the experimental observations of Hong et al. (30). This indicates 
that the decrease in T-cell sensitivity when CD4/pMHC II binding is blocked arises from a 
reduction in TCR phosphorylation by Lck, rather than from de-stabilization of TCR/pMHC II 
binding. It should, however, be noted that the increase in Lck recruitment of a factor of 3 is 
significantly less than the 10-100 fold decrease in sensitivity observed in antibody blocking 
experiments when calcium and IL-2 signalling are monitored (7, 32). A possible explanation 
for this is that the increase in phosphorylation is magnified by the exponential lifetime of the 
TCR/pMHC bond (26) as well as by the requirement for multiple triggering events to act 
cooperatively in producing calcium fluxes and downstream signalling (33). The derived 
expressions also showed that the phosphorylation of previously phosphorylated TCRs is 
significantly, i.e. 30-40 times, faster than the phosphorylation of unphosphorylated TCRs. This 
results from CD4-Lck binding to TCR-P, explaining the observation by Xu and Littman that 
T-cell responses are significantly reduced when Lck cannot bind to TCR-P (27). It also 
indicates that phosphorylation of the first tyrosine(s) in the TCR complex is rate-limiting for 
TCR phosphorylation.  
 
It needs to be emphasized that these calculations are only approximations and their purpose is 
to illustrate how, even with the low affinity we have measured, CD4/pMHC II binding can 
augment T-cell signalling. However, it is also possible that CD4 function and signalling are 
rather more dependent on prior TCR/pMHC II engagement, because this could facilitate CD4 
recruitment (in the ways shown in Fig. S9). Other processes, e.g. phosphorylation by tyrosine 
kinases not associated with CD4, might also affect initial signalling rates. It is furthermore 
possible that since the local concentration of CD4-Lck is increased in the immunological 
synapse (31), this could start to stabilize TCR-P/pMHC II in the synapse according to Eq. 3, 
which would also increase sensitivity. It is clear that more experiments are therefore needed to 
completely understand the role of CD4 in T-cell activation, but our data provides two important 
new insights. First, the interaction of CD4 with pMHC II is very weak but measurable and 
specific, and second, at this low affinity, CD4 binding can enhance TCR phosphorylation 
without significantly stabilizing TCR/pMHC binding. Too low a Kd for the CD4/pMHC II 
interaction would have detrimental effects on the discrimination of self from non-self peptides, 
whereas a too high Kd would result in too few interactions with pMHC II molecules for 
signalling to be enhanced via the delivery of CD4-Lck to the binary TCR/pMHC II complex. 
 
 
Materials and Methods 
The materials and methods used are summarised below; detailed information is given in the SI. 
 
Solution affinity and bead-binding experiments. sCD4 protein, and soluble, biotinylatable 
forms of DR1/HA (residues 307-318:PKYVKQNTLKLA), DR2/MBP (residues 85-
99:ENPVVHFFKNIVTPR), DR4/EBV (residues 627-641:TGGVYHFVKKHVHES) and 
A24/Den2 (residues 555-564:INYADRRWCF) were produced as described previously (34, 
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35). For testing for binding to sCD4, the biotinylated pMHC II were immobilized on Biacore 
streptavidin-coated chips at levels of 1600 RU (DR1/HA), 1750 RU (DR2/MBP) and 1840 RU 
(DR4/EBV). A24/Den2, a kind gift or Prof. T Dong, was immobilized as a negative control at 
1600-1900 RU. The affinities of WT and Q40R-mutated rat CD48 were measured as described 
previously (23). 
 
For the bead binding assay, HEK 293T cells were transfected with constructs encoding 
fluorescent HA-DR1-GFP or gp120-GFP as a control (see SI Materials and Methods, Section 1 
for details). To generate CD4-coated beads 10 µg biotinylated sCD4 protein was incubated 
with 6.7×106 magnetic streptavidin beads M-280 (Dynal biotech). HEK 293T cells were 
transiently transfected by calcium phosphate precipitation with alpha and beta chain constructs 
to express WT or mutant HA-DR1-GFP molecules (see Fig. S4), or gp120-GFP controls. 
Following magnetic “pull-down”, cells were either viewed by fluorescence microscopy and 
counted in duplicate microscope fields or absolute numbers of cells recovered were determined 
using a hemocytometer.  
 
2D affinity measurements. An SLB consisting of 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) from Avanti Polar Lipids with 5-10 wt% of 1,2-dioleoyl-sn-glycero-
3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl] (Nickel salt) (DGS-NTA; 
Avanti Polar Lipids) was formed by vesicle fusion. After formation of the SLB the solution 
was exchanged with a protein mixture of either: (i) polyhistidine-tagged human CD2 (labelled 
with Alexa Fluor® 488) and human CD4 (labelled with Alexa Fluor® 647) for the CD4/pMHC 
II measurements and (ii) polyhistidine-tagged rat CD2 (labelled with Alexa Fluor® 488) and 
human CD58 (labelled with Alexa Fluor® 647) for the CD2/CD48 measurements.  
 
Raji B-cells or Jurkat cells expressing either WT or weakly binding Q40R mutant CD48 were 
added to the protein-coupled SLBs and were allowed to settle for ~60 minutes before imaging. 
Number of proteins on the cell surface, Nt, was determined by flow cytometry and Quantibrite 
analysis with saturating concentrations of PE-conjugated monoclonal antibodies (see SI 
Materials and Methods, Section 2 for details).  
 
Fluorescence imaging was performed in total internal reflection mode with simultaneous 
imaging of the sample at 488 nm and 647 nm (see SI Materials and Methods, Section 2 for 
details of the microscope setup). Images of ~50 cells were acquired for each SLB. SLB protein 
densities were calculated using fluorescence correlation spectroscopy and the images were 
analyzed as detailed in the SI Materials and Methods, Section 2 to obtain B/F and B×p. Scell 
was obtained from a bright-field image of the cell. Photobleaching measurements were 
performed with the same microscopy setup as described in the SI Materials and Methods, 
Section 2.  
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Figure 1. The interaction of CD4 with pMHC II in solution is very weak. (A) SPR-data showing 
the response when passing sCD4 over a sensor surface presenting immobilized biotinylated 
pMHC II molecules (DR1/HA; ○), or a pMHC I molecule (A24/Den2; ◊) as a control. (B) 
Number of isolated pMHC II (HA-DR1-GFP)-expressing HEK 293T cells that bound to 
biotinylated sCD4-coated beads. Error bars show ± one SEM. (C) A bright-field image of cells 
with bound sCD4-coated beads (left panel); white and black arrows identify individual or 
clustered cells expressing or not expressing HA-DR1-GFP based on a corresponding 
fluorescence image (right panel).  
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Figure 2. The native CD4 binding site of  pMHC II. (A) The surface of HLA-DR1 (PDB ID 
code 3S4S) is shown over a ribbon representation of its secondary structure (alpha chain in 
blue; beta in purple). The surface corresponding to residues that are buried by CD4 in the 
complex is highlighted in yellow. (B) Two orthogonal surface views showing residues whose 
mutation disrupts binding to CD4 (red), and residues whose mutation has no effect (green). (C) 
Histogram showing the numbers of cells recovered via the binding of CD4-coated magnetic 
beads, for each of the mutant proteins. Error bars show ± one SD. 
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Figure 3. Fluorescence images showing different degrees of accumulation of CD4 and CD2 
beneath the B cell shown in the bright-field images to the right. The dashed line in the bright-
field images shows the contour of the SLB/cell contact identified by CD2 accumulation. 
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Figure 4. Zhu-Golan curves showing the relative accumulation of ligands for three different 
protein-pair interactions: rat CD2/CD48 (WT; +), rat CD2/CD48 (Q40R; ▼) and CD4/pMHC 
II (○). The solid lines are linear fits to Eq. 1, with Nt×f and Scell fixed, yielding Kd for the 
different interactions. The panel on the right shows the spread of CD4/pMHC II data across a 
smaller scale. 
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Figure 5. The interaction between CD4 and pMHC II increases the phosphorylation rate of 
TCR, but has less influence on the TCR/pMHC II stability. (A) Schematic illustrations showing 
how binding of CD4-Lck to pMHC II increases the rate of initial TCR phosphorylation. (B) 
Binding of CD4-Lck to TCR-P increases the rate of phosphorylation by recruitment of Lck, 
while having only a modest effect on the effective affinity of the TCR/pMHC II complex. 
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Table 1. Values for the 2D Kd analysis and corresponding solution (3D) Kd values.  
 CD4/MHC IIa CD2/CD48 (WT) CD2/CD48 (Q40R) 
Nt 570 000 ± 180 000b 95 000 ± 12 000 310 000 ± 50 000 
Scell 550 ± 70 µm2 690 ± 50 µm2 500 ± 80 µm2 
2D Kd 4800 mol./µm2 38 mol./µm2 380 mol./µm2 
3D Kd >2.5 mM 37 µM 440 µM 
a Protein in the SLB/protein in the contacting cell. 
b Values are presented as mean ± one SD. 
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SI Text 
Section 1. Mutation analysis of the CD4 binding site of DR1. Using both the multivalent 
binding assay, in which DR1-expressing cells are recovered with a magnet following their 
binding of sCD4biot-coated magnetic beads, and in vitro mutagenesis, we mapped the region 
of DR1 bound by CD4. Specifically, we tested whether the crystal structures of the human 
sCD4/mouse H-2Ak complex (6) or of an affinity-enhanced form of CD4 complexed with DR1 
and DR4 (5, 19), in which CD4 binds in a cleft between the α2 and β2 domains of the DR 
molecules, correctly models the interaction of the native human proteins. We also sought 
clarification of whether or not CD4 also binds a second site on α2 identified by König et al. 
that might be responsible for the oligomerization of CD4/pMHC II complexes (20, 21).  
  
We used a “drastic” mutagenesis strategy in which size and and/or charge changes are made to 
individual side chains in order to maximize the likelihood of significantly altering interface 
residues. None of the mutations we introduced substantially reduced DR1 expression by the 
transfectants (see Fig. S4C), indicating that the mutations affect surface-exposed residues 
rather than residues important for folding. Mutations T90R and L92R of α2, and I148R and 
L158R of β2 each reduced the recovery of HA-DR1-GFP expressing cells by sCD4biot-coated 
beads more than 50% (see Fig. 2C), revealing that human CD4 binds pMHC II in the same way 
that it binds mouse pMHC II and in the way that the affinity-enhanced form of CD4 binds to 
DR1 and DR4, i.e. in a pocket formed by the α2 and β2 domains of pMHC II. Our data are 
consistent with the analysis of König et al. (20) wherein the β2 domain double mutant 
E137A/V142A disrupted CD4 binding (see Fig. 2C). However, it now seems likely that this is 
attributable to indirect effects on the structure of the CD4-binding pocket identified 
crystallographically. A second binding site was subsequently proposed by König et al. (21) on 
the grounds that α2 domain mutations prevent CD4 binding. It was proposed that this site 
mediates CD4/pMHC II complex oligomerization. However, drastic single mutations of a 
residue in the centre of this region (T129), and of residues immediately adjacent to it (K126 
and T130) had no effect on the interaction of CD4 with pMHC II suggesting that this region 
does not bind CD4 (see Fig. 2C). We conclude that the mutations of König et al. (21,22) may 
have indirectly affected binding and that human pMHC II forms monovalent contacts with CD4 
at a site homologous to that identified in the sCD4/H-2Ak and affinity-enhanced sCD4-DR1 
and sCD4-DR4 complexes.  
 
Section 2. Kinetic binding theory. The surface density of CD4 bound to pMHC II on the B 
cell, B, is related to the surface density of free CD4 in the SLB beneath the cell, F, by the Zhu-
Golan expression (16):  
 
  [S1] 
 
where Nt is the total number of pMHC II molecules on the B cell, f is the mobile fraction of 
pMHC II molecules, Scell is the surface area of the cell and p is the ratio of the SLB/cell contact 
area to Scell. It has been assumed that the influence binding to immobile receptors has on this 
expression can be neglected (16). 
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It can as a first approximation be assumed that the amount of free ligands in the SLB/cell 
contact area, F, is the same as that in the SLB outside the cell contact area, F*. However, as 
has been observed previously by others, this is not necessarily true and can significantly affect 
the analysis, especially when B/F < 1 (16, 17), resulting in negative B*/F* values, where B* is 
the value obtained when assuming F = F*. As an example, for the experiments in this work we 
define B* as being proportional to the difference in ligand intensity from the cell contact and 
the intensity from ligands in the SLB outside the cell contact. If free ligands are depleted from 
the contact, or equivalently if F < F*, then B* can be negative for weakly binding ligands such 
as CD4 binding to pMHC II. However, the expressions in Eq. S2 and Eq. S4 can be used to 
convert from the observed ratio B*/F* to the actual ratio B/F: 
 
  [S2] 
 
where the value (B*/F*)0 is the ratio of B*/F* when no ligands are binding, which is related to 
F/F* by: 
 
  [S3] 
 
The surface density of bound CD4 is given by: 
 
  [S4] 
 
However, in the situation of a brief contact between a T cell and an APC the receptors and 
ligands on the two opposing cell surfaces will not have time to diffuse over the entire cell 
surface and reach a steady state concentration profile. For a short, ~1 s, contact the 
concentration profile in a ~1 µm2 T-cell/APC contact can instead be approximated by assuming 
immobile ligands and receptors resulting in: 
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where [CD4/pMHC II] is the surface density of CD4 bound to pMHC II molecules and [CD4] 
and [pMHC II] is the surface density of CD4 and pMHC II, respectively, on the two cells 
previous to the cell-cell contact. For the situation when either: (i) Kd is larger than both [CD4] 
and [pMHC II] or (ii) when [pMHC II] >> [CD4], or [CD4] >> [pMHC II], the expression in 
Eq. S5 can be approximated with: 
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where the second equality is valid when Kd >> [CD4] + [pMHC II]. It also follows that if Kd >> 
[CD4] + [pMHC II] then the fraction of pMHC II molecules that have CD4 bound will be 
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independent on the actual number of pMHC II. The number of CD4 binding events per second 
to a single pMHC II molecule is under these conditions given by: 
( ) [ ][ ] [ ]CD4IIpMHC
IICD4/pMHCIICD4/pMHC onoff kkn ≈=  [S7] 
where the last expression is approximately valid when Kd >> [CD4] + [pMHC II]. 
Section 3. Accuracy of the CD4/pMHC II 2D Kd. The curve fit to the CD4/pMHC II data in 
Fig. 4 yields that Kd is between 4200 to 5300 molecules/μm2 with 95% confidence. However, 
this does not allow for possible errors in choosing (B*/F*)0 or errors in averaging the cell data 
to one value for each SLB. A spread in Nt and Scell depending on cell cycle and the protein 
turnover will also add to the uncertainty, as will the assumption that f = 1, which might be 
lower for the present experiments, even though it has in previous studies been observed to be 
relatively high, and close to one, for similar systems (16, 36). The obtained value of the 2D Kd 
should therefore only be seen as an order of magnitude estimate of the CD4/pMHC II 2D Kd. 
Section 4. Measure of CD4 turnover using photobleaching. Equation S1 assumes that the 
CD4/pMHC II interaction has reached equilibrium. However, CD4 is constantly detaching 
from and rebinding the pMHC II. This can be observed by photobleaching an area of the 
SLB/cell contact (24, 29, 37). Fluorescence recovery will, in addition to the sizes of the contact 
and bleached region, depend on the diffusivity of CD4 both in the contact and in the SLB, and 
the on- and off-rates for CD4/pMHC II binding (37). Fluorescence recovery after 
photobleaching was used to study the mobility of CD4 in the SLB/B-cell contact. A delimited 
area in the contact was bleached and the subsequent recovery of fluorescently-labelled CD4 
studied (see Fig. S7). The solid line in Fig. S7B is a fit of the recovery giving an average 
diffusivity of D = 0.16±0.06 µm2/s (N = 4) for CD4 in the contact. This value is ten times 
smaller compared to the diffusivity of free CD4 outside of the contact, which was 
1.8±0.2 µm2/s (N = 4). A reduction in D of similar magnitude has been observed for other 
proteins in SLB/cell contacts (29). 
The recovery will also be affected by the diffusivity outside of the contact, but since the 
bleached region is mainly confined to the contact area this effect has only a minor influence. 
The recovery can also depend on the binding parameters of the CD4/pMHC II interaction, i.e. 
the kinetics of binding (37). If the diffusivity is slow compared to the unbinding of the ligand, 
i.e. if 1/koff > w2/4D, where koff is the off-rate and w the Gaussian radius of the bleached area 
at t = 0, then the recovery will be affected by the binding kinetics and D will no longer only be 
a measure of the diffusivity of CD4. However, for this to be the case in the current experimental 
range the off-rate has to be smaller than 0.07 s-1. This value is much lower than values obtained 
for typical T-cell/B-cell protein interactions in solution (13, 29), and single molecule studies in 
2D (12, 13). The weak CD4/pMHC II interaction can thus be expected to have a koff much 
larger than 0.07 s-1 and recovery should mainly be governed by diffusion in the contact. 
However, it has previously been observed that the 2D koff values obtained from photobleaching 
experiments can be considerably lower than the values measured in solution, due perhaps to 
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increased rebinding, and Tolentino et al. obtained a kinetic off-rate of 0.07 s-1 for rat CD2/CD58 
binding (29). It is therefore possible that the recovery is affected by binding kinetics, but due 
to the small amounts of bound CD4 and the slow recovery in the current experiments this is 
hard to quantify with certainty from our data. Multiple rebinding of CD4 to pMHC II during 
the recovery can also result in a drop in diffusivity. The effective diffusion coefficient, Deff, 
will in this case be given by (38): 
 
 ( ) 1eff 1 −+×= FBDD  [S8] 
 
However, with B/F in the range 0.2 - 0.25 for the CD4/pMHC II interaction this would only 
give a reduction in the diffusivity by ~20%. Thus, the tenfold drop in diffusivity of CD4 in the 
SLB/cell contact is more likely to be caused by a higher net drag of the protein in the contact, 
rather than caused by specific CD4 binding events. 
 
 
Section 5. Recruitment of CD4-Lck to non-phosphorylated TCR/pMHC II. CD4-Lck can 
only phosphorylate the TCR complex when it is within a certain area, A, around the 
TCR/pMHC II. For randomly moving molecules there will on average be A×Rt molecules in 
this area, where Rt is the density of CD4-Lck. If A×Rt < 1 this corresponds to the fraction of 
time a CD4-Lck molecule is close enough to phosphorylate the TCR. It can be assumed that 
Lck is within area A when CD4-Lck binds to pMHC II in a TCR/pMHC II pair, which means 
that bound CD4-Lck can phosphorylate the TCR/pMHC II complex an extra fraction Rt/Kc of 
the time (see Eq. S6), where Kc is the 2D Kd of the CD4/pMHC II interaction. This assumes 
that both Rt and the amount of pMHC II is much less than Kc, and for a general expression Eq. 
S5 should be used. Combining these two expressions results in the formula in Eq. 2. 
 
Section 6. Equilibrium models to describe the distribution of CD4-Lck, TCR-P and 
pMHC II. We consider an equilibrium model consisting of the different states depicted in Fig. 
S8. Only the effect of Lck molecules associated with CD4 (CD4-Lck) are considered. The 
parameters Kc, Kl and K are the 2D Kd values for CD4-Lck to pMHC II, CD4-Lck to TCR and 
TCR to pMHC II, respectively. The parameters Kc* = Kc/σ, Kl* = Kl/σ and K* = K/σ are 
effective 2D Kd values for (re)binding of the same protein pairs in the ternary complex. The 
parameter σ corresponds to the local concentration of the protein molecules upon rebinding in 
the ternary complex, which as an order of magnitude approximation have been set equal for all 
three interactions. The parameter σ can also be defined as 1/A, where A is the area within which 
the molecules have to be to be able to interact. The total surface density of pMHC II, CD4-Lck 
and phosphorylated TCR (TCR-P) is designated P t, Rt and Tt, respectively, and the unbound 
fraction of these molecules are designated Pf, Rf and Tf. It is assumed that in the early stages 
of T-cell activation the fraction of TCR-P is much lower than the total amount of CD4-Lck. 
The influence of CD4, without Lck, binding to pMHC II is neglected in the model due to the 
low affinity between CD4 and pMHC II. From the density of free pMHC II, free TCR-P and 
free CD4-Lck in the T-cell/APC contact, and the equilibrium relations between the different 
states in Fig. S8, the following three coupled equations are obtained:  
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The density of TCR-P molecules bound to pMHC II, nT+P, is given by: 
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and the fraction of TCR-P molecules binding pMHC II is then: 
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The density of CD4-Lck molecules bound to TCR/pMHC II complexes, nR/T+P, is given by: 
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which combined with Eq. S12 gives the fraction of TCR/pMHC II complexes with CD4-Lck 
bound: 
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Some approximations to the expressions presented above can be made under the present 
conditions. Equation S15 can, when Pt and Rt << Kc and Tt << Rt (or when Rf ~ Rt), 
approximately be written: 
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For the situation when Kl → ∞, corresponding to non-phosphorylated TCRs, Eq. S16 simplifies 
to nR/T+P/nT+P = Rt/Kc equivalent to the fraction of CD4 bound to pMHC II given by Eq. S6. 
The effective phosphorylation rate of TCR-P by CD4-Lck, kp, CD4-Lck/TCR-P, can be estimated 
from Eq. S16 as: 
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where kp, Lck/TCR is the phosphorylation rate of TCR by Lck (see also Eq. 2). 
 
The increase in the fraction of TCR-P/pMHC II with Lck due to the CD4/pMHC II interaction 
is under these conditions: 
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Equation S13 can under the same conditions as for Eq. S16 be written: 
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where 1/Keff under these conditions corresponds to the effective affinity of TCR-P to pMHC II. 
Equation S19 can be used to estimate the increase in affinity of TCR-P to pMHC II due to CD4.  
 
Flow-cytometric analysis was used to give totals of 34 000 and 100 000 for the number of CD4 
and pMHC II receptors expressed by naïve T- and B-cells, respectively. A total surface area of 
~200 µm2 for both cell types (Scell = 1.8×πd2 (16), where d = 6 µm is the cell diameter (39, 40)) 
gives a CD4 density of 170 molecules/µm2 and pMHC II density of 500 molecules/µm2. Both 
Rt and Pt is thus significantly smaller than Kc = 5000 molecules/µm2, in agreement with the 
assumptions leading to Eqs. S16, S18 and S19. If it is assumed that 40% of the CD4 molecules 
are coupled with Lck (41), and that between 2% and 40% of the CD4-Lck are constitutively 
active (42, 43), then for Kl = 250 molecules/µm2 (28) we get Rt/Kl ≈ 0.01 to 0.1. This is 
comparable to theoretical values of Rt/Kl = 0.01 used in previous estimates of the stabilizing 
effects of CD4/pMHC II interactions (8). Inserting Rt/Kl = 0.01 and 0.1 into Eq. S19 with σ = 
10000 molecules/µm2 and Kc = 5000 molecules/µm2, gives an apparent affinity increase of 2% 
and 20%, respectively, when K << σ. The same values inserted into Eq. S18, with Kl = 250 
molecules/µm2, gives an increase in the fraction of TCR-P/pMHC II with Lck of 2.6 to 3.0. 
CD4-Lck binding to TCR-P will also increase the recruitment of CD4 compared to when it is 
binding only pMHC II. From Eqs. S6 and S16 it follows that CD4 is recruited ~50-fold more 
efficiently to TCR-P/pMHC II compared to pMHC II alone, although the effective increase 
will be less because only a fraction of the CD4 is likely associated with constitutively active 
Lck and thus able to bind TCR-P. 
 
Section 7. Estimation of kinetic rate constants. The koff value for the CD4/pMHC II 
interaction could not be determined in the present study, and so it is unclear whether the high 
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Kd is due to a low kon value or a high koff value, or a combination of both. However, Wang et 
al. used affinity-maturation to produce a form of CD4 that bound pMHC II with a 3D koff of 
~0.5 s-1 and a 3D Kd of 10 µM (5). Conversion of the 3D Kd to a 2D Kd using the relationship 
obtained experimentally for the rat CD2/CD48 interactions in Table 1 gives a 2D Kd of 
approximately 10 molecules/µm2 for the affinity-matured interaction. This should, however, 
only be considered as an order of magnitude estimate since the ratio between 3D and 2D Kd 
can vary substantially between different protein molecules (11–14). If it is furthermore 
assumed that the mutations made by Wang et al. mostly affect koff, based on the observation 
that the primary effect of the mutations was to improve the geometric fit of CD4 to pMHC II 
(5), the 2D kon and koff values would be of the order of 0.05 µm2s-1 and 250 s-1, respectively, 
for wild-type CD4/pMHC II interactions.  
 
With [CD4] = 170 molecules/µm2 and kon = 0.05 µm2s-1, the number of CD4 binding events 
per second for an individual pMHC II molecule would be around 9 (see Eq. S7). If it again is 
assumed that 40% of the CD4 molecules are coupled with Lck (41), and that between 2% and 
40% of the CD4-Lck are constitutively active (42, 43), this corresponds to each individual 
pMHC II molecule binding a constitutively active CD4-Lck, on the order of 0.1 to 1 times per 
second. It was recently suggested that “kinetic-proofreading”, a mechanism proposed to allow 
the TCR to distinguish between pMHC of differing antigenic quality, may rely on the sampling 
of many CD4 molecules (9). Although the values for kon and koff for the CD4/pMHC II 
interaction are only estimates, it is feasible that the relatively large kon value, makes it possible 
for each pMHC II to interact with multiple CD4 ligands during its time in the cell-cell contact. 
This would be important if only a fraction of the CD4 molecules are associated with Lck. 
 
 
SI Materials and Methods – Section 1. 3D affinity 
Cells and protein expression. HEK 293T cells were maintained in RPMI 1640 media 
supplemented with 10% heat inactivated fetal calf serum, 1% penicillin/streptomycin (50 IU/ml 
and 50 µg/ml) and 1% glutamine. The HEK 293T cells were transfected using calcium 
phosphate precipitation to express pMHC II molecules. Briefly, 0.5 × 106 cells were transfected 
with 0.5 µg of each alpha and beta chain construct, and expression was confirmed by 
fluorescence-activated cell sorting (FACS) analysis using an anti-HLA-DR-phycoerythrin 
(L243 clone) monoclonal antibody. 
 
Construction of HLA-peptide constructs and expression. The DRA*01 sequence was 
cloned into the pcDNA3.1 Hygromycin expression vector (Invitrogen). The DRB1*01:01 
sequence was cloned into the pEGFP-N1 expression vector (Clontech Laboratories) such that 
the EGFP domain was continuous with the C-terminal cytoplasmic tail. In addition, the 
Influenza Hemaglutinin (HA) peptide (residues 307-318: PKYVKQNTLKLA) was covalently 
tagged to the N-terminus via a 12 amino acid Gly-Gly-Ser repeat, and the DRB3*01:01:02:01 
leader sequence preceded the peptide (see Fig. S4A). Site specific mutations were introduced 
via two stage over-lap PCR. The biotinylated DR1/HA complex was produced as described 
previously for HLA-DRB1*04:01/HA (35). Four biotinylated HLA-peptide complexes (34, 
35) were used in the solution binding assays studies: DR1/HA (residues 307-
318:PKYVKQNTLKLA), DR2/MBP (residues 85-99:ENPVVHFFKNIVTPR), DR4/EBV 
(residues 627-641:TGGVYHFVKKHVHES) and A24/Den2 (residues 555-
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564:INYADRRWCF). The A24/Den2 complex was a kind gift from Prof. Tao Dong, 
Weatherall Institute of Molecular Medicine, University of Oxford, UK.  
 
CD4 expression and biotinylation. sCD4 protein was produced as described previously (18) 
but expressed with a tag comprising a biotinylation sequence (GLNDIFEAQKIEWHE; sCD4-
BirA). sCD4-BirA was biotinylated using an Avidity Biotinylation kit. Briefly, sCD4-BirA 
protein in 3.5 ml biotinylation buffer (20 mM Tris, pH 7.5, 25 mM NaCl, 7.5 mM MgCl2) was 
incubated with 400 µl Biomix A (0.5 M bicine buffer, pH 8.3), 400 µl Biomix B (100 mM 
ATP, 100 mM MgOAc, 500 µM biotin), 100 µl d-biotin (500 µM) and 7 µl BirA enzyme (1 
mg/ml) at room temperature for 3.5 hours. The protein was purified by FPLC using 150 mM 
NaCl, 20 mM Tris (pH 8) buffer through a Sephadex-75 column. The protein was concentrated 
using Centricon-30 (Amicon) at 1700xg to a final concentration of 1 mg/ml, achieving 
approximately 60% yield. The control soluble recombinant protein used for ™ studies was a 
rat CD48-CD4 chimera (rCD48-CD4), containing CD4 domains 3 and 4 and CD48 
extracellular domains; this was expressed and biotinylated as previously described (23).  
 
CD4 tetramer and bead formation. CD4 biotinylated protein (sCD4biot) was mixed with 
streptavidin-PE (Molecular Bioprobes) in a 4:1 molar ratio, and tetramers were allowed to form 
for at least 16 hours at 4 °C. The concentration of the tetramer is given as the concentration of 
CD4-biotin protein in the sample. To generate CD4-coated beads 10 µg sCD4biot was 
incubated with 6.7×106 magnetic streptavidin beads M-280 (Dynal biotech). Streptavidin beads 
were washed five times in cold PBS and were then incubated with CD4-biotin protein overnight 
at 4 °C; unbound protein was removed by washing the beads five times with cold PBS.  
 
SPR measurements. HIV-1 IIIB gp120 (bac) was from Immuno Diagnostics, supplied by the 
Centralized Facility for AIDS Reagents supported by EU Programme EVA/MRC and the UK 
Medical Research Council. CD4 specific antibodies were RPA-T4 (BD biosciences) and 
ADP318 (Evans Medical Ltd). For the experiments where soluble CD4 was added to the 
solution, Biacore™ flowcells were coated with streptavidin and biotinylated pMHC molecules 
were immobilized as follows: DR1/HA at 1600 RU, DR2/MBP at 1750 RU, DR4/EBV at 1840 
RU and A24/Den2 as negative control at 1600-1900 RU. Experiments were also made where 
sCD4biot was immobilized onto streptavidin coated sensor surfaces. For measurement of the 
affinities between rat CD2 and wild-type and Q40R-mutated rat CD48 (rCD48), a histidine-
tagged form of rat CD2 expressed in Chinese hamster ovary cells (44) was injected over ~1200 
RU of immobilized biotinylated wild-type and mutant rCD48-CD4 proteins produced as 
described previously (23). 
 
CD4-bead binding to pMHC+ 293T cells. HEK 293T cells were transiently transfected by 
calcium phosphate precipitation with alpha and beta chain constructs to express wild type (WT) 
or mutant HA-DR1-GFP molecules, or gp120-GFP controls. Cells were removed from the flask 
using trypsin/EDTA and washed twice in cold PBS/2% fetal calf serum two days post 
transfection. 3×106 cells in 500 µl PBS were incubated with 6.7×106 CD4 beads on ice for 1.5 
hours with gentle agitation, then the bead/cell conjugates were isolated using a Dynal MCP 
magnetic bead sorter, and resuspended in PBS/2% formaldehyde. Cells were either viewed by 
fluorescence microscopy and counted in duplicate microscope fields or absolute numbers of 
cells recovered were determined using a hemocytometer. Alternatively, CD4-coated magnetic 
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beads were added to HEK 293T cells adhered to wells, and after washing in PBS, bead-bound 
transfected cells were visualized using immunofluorescence microscopy. 
 
FACS measurements. Cells were washed in 5% fetal calf serum/PBS 2 days post transfection 
and incubated with 20 mg/ml CD4-tetramer, or were stained for DR1 expression using anti-
HLA-DR-phycoerythrin (PE) monoclonal antibody (L243 clone), at 4 °C for 30 minutes. Cells 
were then washed in 0.1% azide/PBS and fixed in 2% formaldehyde/PBS for FACS 
acquisition. Figure S4B (left) shows a clear correlation between the amount of WT HA-DR1-
GFP and the binding of anti-DR antibody, whereas no binding of anti-DR antibody is observed 
when gp120-GFP is expressed. When CD4-tetramers were added to the cells expressing WT 
HA-DR1-GFP no binding of CD4 was observed, whereas strong binding of the CD4-tetramers 
was observed for cells expressing gp120-GFP (see Fig. S4B (right)).  
 
 
SI Materials and Methods – Section 2. 2D affinity 
Cleaning of substrates. A glass slide (size no. 1: 0.13 mm in thickness, VWR International) 
was cleaned in a (3:1 by volume) mixture of concentrated sulfuric acid (>95%; Fisher 
Scientific) and 30% hydrogen peroxide (100 vols; Breckland Scientific Supplies) for >3 hrs. 
The sample was then thoroughly rinsed with Milli Q™ water (Millipore) and dried with 
nitrogen gas after which the glass slide was treated with Ar plasma for 10 min (PDC-002; 
Harrick Plasma). A silicone isolator (JTR12R-2.0; Grace Bio Labs) was placed on the glass 
slide following the manufacturer's instructions, to provide a well for the experiments. 
 
Vesicle preparation. Lipid vesicles were prepared by extrusion through a 50 nm membrane 
(Whatman) using an Avanti Mini-Extruder (Avanti Polar Lipids). The vesicles consisted of 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) from Avanti Polar Lipids with either 
5 wt% or 10 wt% of 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic 
acid)succinyl] (Nickel salt) (DGS-NTA; Avanti Polar Lipids). The buffer solution used in all 
experiments was a mixture of 150 mM NaCl (Breckland Scientific Supplies) and 10 mM 
tris[hydroxymethyl]aminomethane (TRIS; Pharmacia Biotech), with a pH of 8.0 (TRIS-
buffer). The buffer solution was filtered through a 0.2 µm membrane (AnaChem) before use.  
 
Formation of lipid bilayers. An SLB was formed by placing a 20 µl drop of the vesicle 
solution in the wells and leaving it for 30-60 minutes before rinsing. The vesicle solution 
containing 10 wt% DGS-NTA was used for the CD4/pMHC II measurements, whereas the 
vesicle solution with 5 wt% DGS-NTA was used for the rat CD2/CD48 measurements. After 
formation of the SLB the buffer solution was exchanged with either of the two protein mixtures: 
 
(i) human CD2 (containing a polyhistidine tag and labelled with Alexa Fluor® 488) and 
human CD4 (containing a polyhistidine tag and labelled with Alexa Fluor® 647) or 
 
(ii) human CD58 (containing a polyhistidine tag and labelled with Alexa Fluor® 647) and 
rat CD2 (containing a polyhistidine tag and labelled with Alexa Fluor® 488), 
 
depending on the measurements. The concentrations of the protein solutions were chosen to 
achieve a final surface coverage after 1 hr of incubation of: 
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(i) ~400 molecules/µm2 for human CD2 and 400-4000 molecules/µm2 for CD4 and 
 
(ii) ~100 molecules/µm2 for human CD58 and 35-1600 molecules/µm2 for rat CD2, 
 
measured using fluorescence correlation spectroscopy (FCS) (45). An SLB containing a known 
amount of fluorescently-labelled lipids (0.01 wt% Oregon Green® 488 1,2-dihexadecanoyl-
sn-glycero-3-phosphoethanolamine; Invitrogen) was used to calibrate the 488 nm beam in the 
FCS. Different SLBs containing mixtures of streptavidin conjugated with Oregon Green® 488 
or Alexa Fluor® 647 (Invitrogen) were used together with the calibrated value for the 488 nm 
beam to calibrate the 633 nm beam for the concentration measurements of the 647-labelled 
proteins.  
 
Cells. B cells or transfected Jurkat cells were added to the wells with the protein-coupled SLBs. 
The cells used for the CD4/pMHC II measurements were Raji B-cells, maintained in B-cell 
medium: RPMI 1640 medium (Invitrogen) supplemented with 10% heat-inactivated fetal 
bovine serum (HyClone; Thermo-Scientific), 1% L-Glutamine (200 mM; Invitrogen), 1% 
HEPES solution (Sigma), 1% sodium pyruvate (100 mM; Invitrogen), 1% 
penicillin/streptomycin (100x; Invitrogen), and kept in an incubator at 37 °C in a humidified 
atmosphere with 5% CO2. Jurkat cells transfected with the protein CD48, either WT or the 
weakly binding mutant Q40R, were also maintained in B-cell medium. Before each 
measurement the cells were resuspended in TRIS-buffer and directly added to the SLB where 
they were allowed to settle and bind to the proteins in the SLB for ~60 minutes before imaging. 
For the measurements at 37 °C the SLB was placed in a temperature control system on the 
microscope where it was heated, and maintained at, 37 °C before adding the cells (also at 37 
°C) and imaging.  
 
Flow Cytometry and Quantibrite analysis. In order to obtain the number of different 
membrane proteins per cell the cells were first washed and resuspended in phosphate buffered 
saline containing 0.05% NaN3 at a concentration of 0.5×106 cells/ml. Staining was performed 
by incubation of the cells on ice for 45 minutes with saturating concentrations of PE-conjugated 
monoclonal antibodies to the following antigens: human CD4 (clone RPA-T4; cat. no. 12-
0049-42, eBioscience), anti-HLA-DR (clone L243; cat. no. 12-9952-42, eBioscience) and rat 
CD48 (clone OX45; cat. no. 204206, Biolegend). After washing, the cells were analyzed by 
flow cytometry on a Cyan ADPTM (Beckman Coulter) alongside with QuantibriteTM PE beads 
(BD Bioscience). A calibration curve was generated from four different concentrations of beads 
with R-PE covalently attached. The calibration curve was used to determine the amount of 
membrane proteins per cell from the geometric mean of the fluorescence intensity according 
to the manufacturer’s instructions. 
 
The microscope setup. The fluorescence imaging was performed in TIRF-mode with an 
inverted Nikon Eclipse TE200 microscope (Nikon Corporation), using a Photometrics Cascade 
II:512 EMCCD camera (Photometrics), and a 60× magnification (Plan Apo TIRF, NA = 1.45) 
oil immersion objective (Nikon Corporation). The acquired images consisted of 512×512 
pixels with a pixel size of 0.11×0.11 µm in the sample plane. Using a Dual-View DV2 two-
channel, simultaneous-imaging system (Photometrics) the left half of this image corresponded 
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to the 647 nm fluorescence and the right half to the 488 nm fluorescence, thus allowing for 
simultaneous imaging of the sample with two wavelengths. A Cyan diode laser operating at a 
wavelength of 488 nm (model no. PC13589; Spectra Physics) and a HeNe laser operating at 
633 nm (model no. 25LHP991230, Melles Griot) were used for illumination. The images were 
acquired with an exposure time of 100 ms, and 10 images were acquired and averaged for each 
image. 
 
Zhu-Golan analysis. Images of approximately 50 different cells were acquired for each SLB. 
These images were normalized using an image of the SLB without any cells to compensate for 
uneven illumination. The intensities in the SLB were converted into surface coverage of 
proteins using the data obtained from the FCS measurements. The contact region for each cell 
was first manually selected by a polygon in the human CD2 (rat CD2 for the Jurkat 
measurements) fluorescence images, leaving sufficient space between the contact region and 
the polygon border to allow the intensity at the polygon border to be used to normalize the 
intensity in the contact region. This was achieved by fitting a plane to the intensity on the 
polygon border, which was then used to normalize the intensity in the contact region. The 
normalized intensity values within the polygon where subjected to a threshold (intensities 
larger than 1/3 the maximum intensity in the polygon) to define the contact region under the 
cell. Averaging the intensity in the contact region gave B*/F*. The amount of accumulated 
protein in the contact was obtained by multiplying B*/F* with the obtained background 
intensity outside of the cell contact region, F*. The same masks for the contact region as 
obtained for the human CD2 images were used to analyze CD4. The area of each cell was 
obtained from a bright-field image of the cell, where the cell was manually encircled with a 
polygon and the area of the cell was calculated as 7.2 times the area of this region (16). Dividing 
the area of the contact region under the cell with the cell area resulted in an estimate of p for 
each contact. 
 
The data was next analyzed to provide a single averaged value of B×p, Scell and B/F for each 
SLB. To avoid analyzing cells where the threshold had produced too-small contact regions, the 
cells with the lowest values of p were removed from the analysis (the lowest 10% was 
removed). All data for B*/F* was plotted vs B*×p and fitted to the expression: 
 
  [S20] 
 
where c1, c2 and c3 are parameters to be fitted (see Fig. S5). Since the contact area fraction, p, 
is of similar magnitude for different B cells binding to the CD4-SLB (mean value of 4% with 
a standard deviation of 1%), as is the density of ligands in the SLB, F*, the ratio B*/F* is 
expected to vary approximately linearly with B*×p. However, this is not the case observed 
experimentally for CD4 binding pMHC II as seen in Fig. S5, where the ratio B*/F* is initially 
constant at a value c1 ≈ -0.25, before it starts to increase linearly with B*×p at B*×p = c2 ≈ -3. 
This can be interpreted as the B cells with B*/F* = -0.25 are not accumulating CD4 in the 
contact, and the value (B*/F*)0 = -0.25 therefore corresponds to the depletion of free CD4 
beneath the cell when CD4 is not binding pMHC II molecules on the B cell. Only data points 
where B*×p are above c2 were therefore used to obtain B/F and B using Eqs. S2 and S4 with 
(B*/F*)0 = c1. For the rat CD2/CD48 measurements c1 = -0.20 and c2 = 0 was assumed, 
estimated from the average value of B*/F* for non-binding Alexa Fluor® 647 labelled rat CD2 
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in the contact between an SLB and a B cell anchored to the SLB with human CD2 (see Fig. 
S6B). 
 
Compensating for bleed through between the 488- and the 647-channel did not yield 
significantly different values for the data, even though a higher intensity in the contact area due 
to bleed through from the 488-channel could be observed at, in particular, low concentrations 
of CD4 in the SLB. However, since this will also be the case for (B*/F*)0 this largely cancels 
out the effect of the bleed through from the corrected plots of B/F. 
 
The data for B/F vs B×p was next fitted to Eq. S1, to obtain Kd. Values for Nt was estimated 
from FACS-based measurements and Scell from bright-field images as described above. The 
parameter f was further set to 1, corresponding to all receptors on the cells being mobile.  
 
Photobleaching measurements. For the fluorescence recovery after photobleaching (FRAP) 
measurements, a set of pre-bleach images were first acquired after which a negative lens was 
positioned in the beam path to cancel out the effect of the Köhler lens in the microscope and 
focus the laser beam into a small region at the centre of the sample. The photobleaching rate 
of the sample was increased by removing some of the ND filters in the laser beam path during 
the bleaching step, thus illuminating the sample with higher intensity during bleaching. After 
a few seconds the ND filters were put back and the negative lens removed. The recovery of 
CD4 was imaged with time-lapse acquisition.  
 
Measurements were made both in the SLB/cell contact and outside this region to estimate the 
diffusivity of CD4 outside the contact. The SLB contained approximately 600 molecules/μm2 
of CD4 in all experiments. The intensity after photobleaching had a Gaussian intensity profile: 
 
  [S21] 
 
where I0 is the intensity before bleaching, K the relative amount of bleaching, r the distance to 
the centre of the bleached area and w the Gaussian radius of this area. The intensity was 
normalized to the value before bleaching and subsequently integrated within a circle of radius 
R = w/21/2. The diffusivity of CD4 was estimated by fitting the integrated intensity to (46):  
 
  [S22] 
 
where α, K and D are parameters to be fitted, D is the diffusivity and R was set to w/21/2.  
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Fig. S1. The sCD4 is correctly folded. Sensograms showing binding of anti-human CD4 
antibodies: (A) ADP318, (B) RPA-T4 and (C) HIV-1 gp120 to a surface coated with sCD4 or 
with the control protein rCD48-CD4. Sequential injections were done in order to confirm that 
saturation binding had been reached, so that the “activity” of the CD4 could be calculated. 
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Fig. S2. Sensograms showing binding of anti-HLA-DR and sCD4 to pMHC II and pMHC I. 
(A) A sensogram showing injection of saturating levels (0.2 mg/ml) of the anti-HLA-DR 
antibody L243 over a sensor surface containing immobilized biotinylated pMHC II molecules 
(DR1/HA; dashed line) or a pMHC I molecule (A24/Den2; solid line) as a control. (B) SPR-
data showing the response when passing sCD4 at 2.5 mM at 4 °C over biotin-immobilized 
DR1/HA and A24/Den2. 
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Fig. S3. The interaction of CD4 with DR2 and DR4 pMHC II in solution is very weak. (A,B) 
SPR-data showing the response when passing sCD4 at a range of concentrations up to 2.5 mM 
at 37 °C or as a single injection at 2.5 mM at 4 °C over a sensor surface containing immobilized 
biotinylated DR2/MBP (- ∙ -; ○), DR4/EBV (∙ ∙ ∙; ∆), or a pMHC I molecule A24/Den2 (─; ◊) 
as a control. (C) A sensogram showing injection of saturating levels (0.2 mg/ml) of the anti-
HLA-DR antibody L243 over the three samples. 
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Fig. S4. (A) Schematic illustration showing the construct used for expression of HA-DR1-GFP. 
(B) FACS data showing binding of (left) anti-DR antibodies and (right) CD4-tetramers on the 
y-axis vs the GFP intensity on the x-axis for HEK 293T cells expressing WT HA-DR1-GFP 
and gp120-GFP. (C) FACS data showing DR1 expression measured using PE-linked anti-
HLA-DR (L243) antibody (y-axis) vs the amount of fluorescence from GFP linked to the 
mutant DR1 proteins (x-axis). 
  
- 37 - 
 
 
Fig. S5. Zhu-Golan plot for a representative SLB showing the apparent amount of bound CD4 
in the SLB/B-cell contact for different cells. The numbers i to iii corresponds to the cases shown 
in Fig. 3. The area encircled with a red, dashed, border is the data points used to obtain an 
average value for B/F for each SLB. 
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Fig. S6. Fluorescence images showing (A) depletion of CD4 and accumulation of rat CD2 in 
the contact to CD48(WT)-transfected Jurkat cells, (B) depletion of rat CD2 and accumulation 
of human CD2 in the contact to B cells, (C) accumulation of rat CD2 and human CD58 in the 
contact to CD48(WT)-transfected Jurkat cells and (D) accumulation of rat CD2 and human 
CD58 in the contact to the weak-binding mutant CD48(Q40R)-transfected Jurkat cells. The 
dashed line in the bright-field images shows the contour of the SLB/cell contact as obtained 
from the accumulation in the middle column of images for each case.  
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Fig. S7. The CD4/pMHC II interaction is dynamic. (A) Representative fluorescence images 
showing fluorescently-labelled CD4 in an SLB/B-cell contact before photobleaching (t < 0 s), 
just after photobleaching (t = 0 s) and t = 120 s after photobleaching. (B) The integrated 
intensity, I, in the centre of the bleached area relative to the value before photobleaching (t < 0 
s). The solid line is a curve fit of the recovery data at t ≥ 0 s (see Eq. S22). (C) Radial intensity 
line profiles. The radial distance r = 0 corresponds to the centre of the bleached region. The 
intensity is normalized to the value before photobleaching. 
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Fig. S8. Schematic illustration showing the different states (X, U, Q, W, S, Z, V and Y) in the 
kinetic modelling, with the equilibrium constants: Kc, Kl, K, Kc*, Kl* and K*. 
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Fig. S9. Binding of CD4 to a TCR/pMHC II complex can potentially increase the affinity of 
CD4 to pMHC II. (A) Schematic illustrations showing how binding of pMHC II to TCR can 
reduce the energy loss associated with membrane fluctuations (47) upon CD4 binding to pMHC 
II and (B) to arrange pMHC II at a suitable distance and position for CD4 binding. 
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Still Image for Video S1. B cells landing and binding to lipid-anchored CD4 and CD2 in an 
SLB. The SLB contained 900 molecules/µm2 of Alexa Fluor® 647-labelled CD4 and 400 
molecules/µm2 of Alexa Fluor® 488-labelled CD2. The last frame is a bright-field image taken 
after 57.5 minutes. 
 
